Best Foundayo (Orforglipron) Providers in 2026 — Ranked & Reviewed
Foundayo (orforglipron) is the first FDA-approved oral GLP-1 receptor agonist for chronic weight management, approved on April 1, 2026 by Eli Lilly. Commercial dispensing started on April 6, 2026 and the provider list is small but growing fast. We track every US telehealth platform and pharmacy confirmed as a Foundayo channel, with pricing tiers verified directly from each provider's website. The Lilly Savings Card brings the price to $25/month for commercially insured patients, $149-$299/month for cash-pay. We update this list weekly as more providers come online.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Quick Picks: Top 5
Detailed Reviews
Amazon One Medical
Best for: the most authoritative branded GLP-1 channel with same-day delivery and integrated manufacturer savings
Amazon One Medical's GLP-1 Weight Loss program is the unified Amazon GLP-1 channel — One Medical clinicians prescribe FDA-approved Wegovy / Zepbound / Foundayo (no compounded products), and Amazon Pharmacy fulfills with same-day delivery in ~3,000 US cities (expanding to 4,500 by year-end 2026) plus in-office kiosk pickup at select One Medical locations. No prior One Medical membership required to enroll. Insurance accepted; cash pay also supported. Foundayo (orforglipron) launched April 9, 2026 at $25/month with insurance + Lilly Savings Card and $149/month cash pay (manufacturer coupons auto-applied). Wegovy and Zepbound pricing varies by insurance; manufacturer savings programs (NovoCare, LillyDirect) are integrated into the checkout. Distinct from telehealth platforms that route brand-name fulfillment through Amazon Pharmacy as a backend — this is the Amazon-prescribing-side program.
Score Breakdown
Pros
- ✓$1/day ($25/month) with insurance and the automatically-applied Lilly manufacturer-sponsored coupon — the cheapest brand-name Foundayo channel we've seen
- ✓Same-day delivery in nearly 3,000 US cities and towns at launch, expanding to 4,500 by year-end 2026 — most aggressive delivery footprint of any GLP-1 distribution channel
- ✓In-office, licensed-pharmacist-supported kiosks at select One Medical locations let patients walk out of an appointment with their Foundayo in hand — bypasses pharmacy lines entirely
- ✓Cash-pay $5/day ($149/month) is competitive with Ro and GoodRx for the same FDA-approved brand-name product
- ✓Real-time medication availability + transparent pricing + automatic manufacturer coupon application before checkout
- ✓Has been delivering GLP-1 medications since 2021 — operational track record on cold-chain biologic logistics
- ✓24/7 access to licensed pharmacists for clinical questions
Cons
- ✗Headline $25/month Foundayo price requires both insurance coverage AND the Lilly Savings Card — uninsured patients pay the $149/month cash price
- ✗Same-day delivery is geographically gated — outside the ~3,000 cities, delivery falls back to next-day, two-day, or three-day depending on remoteness
- ✗Pricing is set by manufacturer (Lilly, Novo Nordisk) savings programs and can change at any time
- ✗Does not offer compounded semaglutide or tirzepatide — brand-name only (Foundayo, Wegovy, Zepbound)
- ✗Wegovy / Zepbound pricing is not publicly disclosed on the Amazon One Medical landing page — it depends on insurance coverage at the prescribing visit. Plan to review final pricing at checkout before committing
- ✗One Medical clinical visits accept insurance, but copays/deductibles still apply for the Scheduled Visit; cash-pay visit pricing is also disclosed on enrollment
LillyDirect Foundayo
Best for: patients with commercial insurance who want the cheapest legal brand-name GLP-1
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. With the Lilly Savings Card, commercially insured patients pay $25/month; cash-pay patients pay $149-$299/month depending on labeled dose. Requires a valid US prescription from any licensed prescriber.
Score Breakdown
Pros
- ✓Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- ✓Direct from manufacturer — no compounding, no third-party reseller
- ✓Daily oral pill, no injections, no refrigeration
- ✓Available in all 50 states
Cons
- ✗Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- ✗Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- ✗$25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- ✗Strict empty-stomach 30-minute window may be hard for some patients to follow
GoodRx
Best for: self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. Offers self-pay discount pricing for brand-name GLP-1 medications — Foundayo (orforglipron) starting at $149/month and Zepbound KwikPen (tirzepatide) starting at $299/month — redeemable at 70,000+ pharmacies nationwide. Also operates GoodRx Care, a telehealth arm offering GLP-1 prescriptions with online visits starting at $39.
Score Breakdown
Pros
- ✓$149/month self-pay price for FDA-approved brand-name Foundayo (orforglipron) — matches the lowest available discounted cash price at launch and is dramatically cheaper than typical retail brand-GLP-1 pricing
- ✓$299/month self-pay for FDA-approved Zepbound KwikPen — significantly under the typical Lilly cash list price
- ✓Honored at 70,000+ US pharmacies nationwide — by far the largest brick-and-mortar redemption network of any GLP-1 distribution channel we cover
- ✓No telehealth membership fee — you bring your own prescription and present the discount card at the pharmacy counter
- ✓Brand-name FDA-approved medication, not compounded — no compounding-pharmacy quality variability or FDA non-evaluation disclaimer
- ✓Pharmaceutical manufacturer-direct pricing model — Lilly is delivering the discounted cash price directly through GoodRx, not a third-party negotiation
- ✓GoodRx Care telehealth arm offers online GLP-1 prescriptions ($39–$70 per visit, or $19 with Gold membership) — one-stop shop for both the prescription and the discount card
Cons
- ✗Requires a valid prescription — GoodRx is a discount card, not a telehealth provider. You still need a clinician to write the script (your existing PCP, an endocrinologist, or a separate telehealth visit)
- ✗Self-pay only — does not coordinate with insurance benefits or apply toward insurance deductibles
- ✗Pricing applies only to the lowest Foundayo dose at the headline number; higher doses may carry different pricing not disclosed in the launch
- ✗Does not include compounded GLP-1s — if you want compounded semaglutide or tirzepatide, this is not the channel
- ✗GoodRx is publicly traded (NASDAQ: GDRX) and pricing is subject to change as Lilly's manufacturer-sponsored coupon program evolves
WeightWatchers
Best for: Foundayo access with a structured behavior-change program
WeightWatchers offers Foundayo (orforglipron) through its Med+ program, with care delivered by the WeightWatchers Clinic affiliate medical group. Foundayo is self-pay at $149/mo for the starting dose and up to $299/mo at higher doses, billed separately from the Med+ membership ($25 first month, $74/mo after with a 12-month commitment). WW is one of the few non-pharmacy telehealth programs that lists Foundayo transparently.
Score Breakdown
Pros
- ✓One of the first non-pharmacy telehealth programs to list Foundayo transparently
- ✓Care delivered by WeightWatchers Clinic (affiliated medical group)
- ✓Supports all 6 Foundayo doses: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg
- ✓Publishes self-pay drug price on the product page (rare for a telehealth program)
- ✓Combines pharmacotherapy with the WW Points/behavior-change program
Cons
- ✗Med+ membership ($25 first month, $74/mo ongoing) is billed separately from the drug cost — actual out-of-pocket is higher than the listed $149/mo
- ✗State availability list not published publicly — requires eligibility quiz
- ✗Insurance coverage for Foundayo not yet available per WW's own disclosure
- ✗No compounded GLP-1 option; Foundayo only
- ✗12-month Med+ commitment required to lock the introductory $25 price
Ro
Best for: broadest GLP-1 formulary including Foundayo on day-one of launch
Ro is one of the largest direct-to-patient telehealth companies in the US and operates the most comprehensive obesity care formulary in the category — compounded semaglutide, brand-name Wegovy and Zepbound, and as of April 9 2026, Eli Lilly's new oral GLP-1 Foundayo (orforglipron) starting at $149/month for the lowest dose plus membership.
Score Breakdown
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Cons
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Related Rankings
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Orforglipron · Drugs and brands
- Foundayo · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism
- STEP-1 · Major trials
- Compounded GLP-1 · Pharmacy and drug forms
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.